Late-stage data also showed that Johnson & Johnson’s icotrokinra was superior to Bristol Myers Squibb’s Sotyktu at clearing ...
MedPage Today on MSN2d
TYK2 Inhibitor Scores Two Wins Outside Plaque PsoriasisThe TYK2 inhibitor deucravacitinib (Sotyktu) showed clinical potential in two diseases other than psoriasis, according to ...
Bristol-Myers Squibb (NYSE:BMY) on Saturday announced results from a late-stage trial for its psoriasis therapy Sotyktu in ...
ESK-001 is a highly selective, next-generation oral tyrosine kinase 2 (TYK2) inhibitor currently under development in moderate-to-severe plaque ...
ORKA-001, targeting IL-23p19, Phase 1 trial ongoing, with pharmacokinetic (PK) data expected in 2H 2025ORKA-001 Phase 2a initiation expected in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback